<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468426</url>
  </required_header>
  <id_info>
    <org_study_id>1336-0011</org_study_id>
    <secondary_id>2017-001378-41</secondary_id>
    <nct_id>NCT03468426</nct_id>
  </id_info>
  <brief_title>A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours</brief_title>
  <official_title>An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With Ezabenlimab to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer and in Other Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has 2 parts. The first part was open to adults with advanced non-small cell lung&#xD;
      cancer. The second part was open also to adults with other types of advanced cancer of the&#xD;
      lung, brain, skin, and liver. After early encouraging results, more people with liver cancer&#xD;
      can now take part in the study. The participants get a combination of two medicines called BI&#xD;
      836880 and ezabenlimab.&#xD;
&#xD;
      BI 836880 is a type of an antibody that blocks new blood vessel formation. New blood vessels&#xD;
      are needed by the tumour to continue growing. Ezabenlimab is an antibody that may help the&#xD;
      immune system fight cancer (immune checkpoint inhibitor).&#xD;
&#xD;
      The purpose of the first part of the study was to find out the highest dose of the BI 836880&#xD;
      that the participants can tolerate in combination with BI 754091. After the best dose of BI&#xD;
      836880 for the combination with ezabenlimab was found, it is used in the second part of the&#xD;
      study. The purpose of the second part is to see whether the combination of BI 836880 and BI&#xD;
      754091 is able to make tumours shrink.&#xD;
&#xD;
      The participants are in the study as long as they benefit from and can tolerate treatment.&#xD;
      During this time, they get infusions of BI 836880 and ezabenlimab every 3 weeks. The doctors&#xD;
      also regularly check the general health of the participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">June 19, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 13, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of patients with Dose Limiting Toxicities (DLTs) within the first cycle of treatment</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Objective response</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Adverse events (AEs), drug related AEs, drug related AEs leading to discontinuation during treatment period</measure>
    <time_frame>Up to 294 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 504 hours (AUC 0-504h) after the first infusion cycle</measure>
    <time_frame>Up to 504 hours after first infusion cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 504 hours (AUC 0-504h) after the fourth infusion cycle</measure>
    <time_frame>Up to 504 hours after fourth infusion cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time from dosing to maximum measured concentration of the analyte in plasma (tmax)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Adverse events (AEs), drug related AEs, drug related AEs leading to discontinuation during treatment period</measure>
    <time_frame>Up to 294 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 504 hours (AUC 0-504h) after the first infusion cycle</measure>
    <time_frame>Up to 504 hours after first infusion cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Time from dosing to maximum measured concentration of the analyte in plasma (tmax)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Disease control (DC)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART 2: Duration of objective response (DoR)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Progression-free survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Tumour shrinkage (in millimeters)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">305</enrollment>
  <condition>Non-squamous, Non-Small-Cell Lung Cancer</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BI 836880 + ezabenlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 836880</intervention_name>
    <description>intra-venous infusion</description>
    <arm_group_label>BI 836880 + ezabenlimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezabenlimab</intervention_name>
    <description>intra-venous infusion</description>
    <arm_group_label>BI 836880 + ezabenlimab</arm_group_label>
    <other_name>BI 754091</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part 1:&#xD;
&#xD;
          -  Of full age (according to local legislation, usually ≥ 18 years) at screening.&#xD;
&#xD;
          -  Pathologically confirmed locally advanced or metastatic non-squamous NSCLC with PDL-1&#xD;
             expression available and &gt;1% by IHC (as defined by the Pembrolizumab companion&#xD;
             diagnostic test, determined by appropriate local pathology lab.&#xD;
&#xD;
          -  No previous treatment with check-point inhibitor. Or patients with checkpoint&#xD;
             inhibitor based treatment as last therapy before entering the trial.&#xD;
&#xD;
          -  Documented disease progression or relapse (based on investigator's assessment) during&#xD;
             or after completion of at least 2 cycles of platinum-based chemotherapy as first line&#xD;
             treatment of Stage IIIB/IV non- squamous NSCLC or for checkpoint inhibitor experienced&#xD;
             patients during or after completion of at least 2 cycles of platinum-based&#xD;
             chemotherapy and a checkpoint inhibitor treatment (monotherapy or in combination with&#xD;
             chemotherapy). This includes patients relapsing within 6 months of completing&#xD;
             (neo)adjuvant/curative-intent chemotherapy/CPI or chemoradiotherapy&#xD;
&#xD;
          -  At least one target lesion (outside the brain) that can be accurately measured per&#xD;
             Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 .&#xD;
&#xD;
          -  Lesion with a diameter ≥ 2cm assessed by radiologist as suitable for DCE-MRI&#xD;
             evaluation (Mandatory in Part 1, optional in Part 2)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 Life expectancy ≥ 3&#xD;
             months after start of the treatment in the opinion of the investigator&#xD;
&#xD;
          -  Recovery from all reversible adverse events of previous anti-cancer therapies to&#xD;
             baseline or CTCAE grade 1, except for alopecia (any grade), sensory peripheral&#xD;
             neuropathy , must be ≤ CTCAE grade 2 or considered not clinically significant.&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH-GCP and local&#xD;
             legislation prior to admission to the trial&#xD;
&#xD;
          -  Availability and willingness to provide a fresh tumour tissue sample obtained at&#xD;
             baseline, and after 2 cycles of treatment&#xD;
&#xD;
          -  Adequate organ function defined as all of the following (all screening labs should be&#xD;
             performed at local lab within 10 days prior to treatment initiation)&#xD;
&#xD;
          -  Male or female patients. Women of childbearing potential (WOCBP)1 and men able to&#xD;
             father a child must be ready and able to use highly effective methods of birth control&#xD;
             per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used&#xD;
             consistently and correctly, starting with the screening visit and through 6 months&#xD;
             after the last dose of BI 836880 and BI 754091 treatment, respectively. A list of&#xD;
             contraception methods meeting these criteria is provided in the patient information&#xD;
             Note: Female patients of childbearing potential must have a negative serum pregnancy&#xD;
             test within 72 hours prior to taking study medication during the screening period. At&#xD;
             the following visits according to the flowchart a urine and/or serum pregnancy test is&#xD;
             required. If the urine test is positive or cannot be confirmed as negative, a serum&#xD;
             pregnancy test will be required. The serum pregnancy test must be negative for the&#xD;
             patient to be eligible.&#xD;
&#xD;
        Part 2:&#xD;
&#xD;
          -  Of full age (according to local legislation, usually ≥ 18 years) at screening&#xD;
&#xD;
          -  At least one measurable target lesion outside the brain (excluding the glioblastoma&#xD;
             patients where brain lesions are allowed), that can be accurately measured per RECIST&#xD;
             version 1.1 or Response Assessment in Neuro-Oncology (RANO)&#xD;
&#xD;
          -  ECOG performance status ≤ 1 (For glioblastoma cohort Karnofsky status is applicable)&#xD;
&#xD;
          -  Adequate organ function as all of the following (all screening labs should be&#xD;
             performed at local lab within approximately 72 hours prior to treatment initiation)&#xD;
&#xD;
          -  Availability and willingness to provide a fresh tumor tissue sample obtained after&#xD;
             relapse or progression on or after prior therapy. For Part 2, In case a fresh biopsy&#xD;
             cannot be obtained (e.g. inaccessible lesions or patient safety concern), an archived&#xD;
             specimen obtained up to 6 months prior to cycle 1, visit 1 (C1V1) may be submitted in&#xD;
             case no systemic antineoplastic therapy has been administered between the biopsy and&#xD;
             C1V1 (except for cohort D). For cohorts E, F and G, a fresh on-treatment biopsy is&#xD;
             mandatory at C3D1, if possible from the same lesion as the pre-treatment biopsy.&#xD;
&#xD;
          -  Life expectancy ≥ 3 months after start of the treatment in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  Recovery from all reversible adverse events of previous anti-cancer therapies to&#xD;
             baseline or CTCAE grade 1, except for alopecia (any grade), sensory peripheral&#xD;
             neuropathy , must be ≤ CTCAE grade 2 or considered not clinically significant.&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH-GCP and local&#xD;
             legislation prior to admission to the trial&#xD;
&#xD;
          -  Male or female patients. Women of childbearing potential (WOCBP)2 and men able to&#xD;
             father a child must be ready and able to use highly effective methods of birth control&#xD;
             per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used&#xD;
             consistently and correctly, for the entire duration of the trial treatment intake and&#xD;
             for 6 months after the end of the trial treatment. A list of contraception methods&#xD;
             meeting these criteria is provided in the patient information.&#xD;
&#xD;
        Note: Female patients of childbearing potential must have a negative serum pregnancy test&#xD;
        within 72 hours during the screening period. At the following visits according to the&#xD;
        flowchart, a urine and/or serum pregnancy test is required. If the urine test is positive&#xD;
        or cannot be confirmed as negative, a serum pregnancy test will be required. The serum&#xD;
        pregnancy test must be negative for the patient to be eligible.- Further inclusion criteria&#xD;
        apply&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Part 1:&#xD;
&#xD;
          -  Known hypersensitivity to the trial drugs or their excipients or risk of allergic of&#xD;
             anaphylactic reaction to drug product according to Investigator judgement (e.g.&#xD;
             patient with history of anaphylactic reaction or autoimmune disease that is not&#xD;
             controlled by nonsteroidal anti-inflammatory drugs (NSAIDs), inhaled corticosteroids,&#xD;
             or the equivalent of &lt;/= 10 mg/day prednisone).&#xD;
&#xD;
          -  Known immunodeficiency virus infection or an active hepatitis B or C virus infection.&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to other mAbs.&#xD;
&#xD;
          -  Immunosuppressive corticosteroid doses (&gt; 10 mg prednisone daily or equivalent) within&#xD;
             4 weeks prior to the first dose of trial medication.&#xD;
&#xD;
          -  Current or prior treatment with any systemic anti-cancer therapy either within 28 days&#xD;
             or a minimum of 5 half-lives, whichever is shorter before start of treatment.&#xD;
&#xD;
          -  Serious concomitant disease, especially those affecting compliance with trial&#xD;
             requirements or which are considered relevant for the evaluation of the endpoints of&#xD;
             the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers&#xD;
             (gastrointestinal tract, skin) or laboratory abnormality that may increase the risk&#xD;
             associated with trial participation or trial drug administration, and in the judgment&#xD;
             of the investigator would make the patient inappropriate for entry into the trial.&#xD;
&#xD;
          -  Major injuries and/or surgery or bone fracture within 4 weeks of start of treatment,&#xD;
             or planned surgical procedures during the trial period.&#xD;
&#xD;
          -  Patients with personal or family history of QT prolongation and/or long QT syndrome,&#xD;
             or prolonged QTcF at baseline (&gt; 480 ms).&#xD;
&#xD;
          -  Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension,&#xD;
             unstable angina, history of infarction within past 6 months, congestive heart failure&#xD;
             &gt; NYHA II).&#xD;
&#xD;
        Uncontrolled hypertension defined as: Blood pressure in rested and relaxed condition &gt;= 140&#xD;
        mmHg, systolic or &gt;= 90 mmHg diastolic (with or without medication), measured according to&#xD;
        Appendix 10.2.&#xD;
&#xD;
          -  LVEF &lt; 50%&#xD;
&#xD;
          -  History of severe hemorrhagic or thromboembolic event in the past 12 months (excluding&#xD;
             central venous catheter thrombosis and peripheral deep vein thrombosis).&#xD;
&#xD;
          -  Known inherited predisposition to bleeding or to thrombosis in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Patient with brain metastases that are symptomatic and/or require therapy.&#xD;
&#xD;
          -  Patients who require full-dose anticoagulation (according to local guidelines). No&#xD;
             Vitamin K antagonist and other anticoagulation allowed; LMWH allowed only for&#xD;
             prevention not for curative treatment.&#xD;
&#xD;
          -  History of pneumonitis within the last 5 years&#xD;
&#xD;
          -  Patients who are under judicial protection and patients who are legally&#xD;
             institutionalized.&#xD;
&#xD;
          -  Patients unable or unwilling to comply with protocol&#xD;
&#xD;
          -  Previous enrolment in this trial (Part 1 or Part 2).&#xD;
&#xD;
          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,&#xD;
             makes them an unreliable trial patient or unlikely to complete the trial.&#xD;
&#xD;
          -  Women who are pregnant, nursing, or who plan to become pregnant in the trial&#xD;
&#xD;
        Part 2:&#xD;
&#xD;
          -  Known hypersensitivity to the trial drugs or their excipients or risk of allergic of&#xD;
             anaphylactic reaction to drug product according to Investigator judgement (e.g.&#xD;
             patient with history of anaphylactic reaction or autoimmune disease that is not&#xD;
             controlled by nonsteroidal anti-inflammatory drugs (NSAIDs), inhaled corticosteroids,&#xD;
             or the equivalent of &lt;/= 10 mg/day prednisone).&#xD;
&#xD;
          -  Not more than one CPI based treatment regimen prior to entering study (e.g.&#xD;
             anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1),&#xD;
             anti-PD-L2, or anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4)&#xD;
             antibody). In case of CPIs combination, they need to be approved by the local&#xD;
             regulatory agencies; for e.g., Melanoma cohort (Cohort E).&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (exception for&#xD;
             patients in HCC cohorts; Cohorts F&amp; G).&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to other mAbs.&#xD;
&#xD;
          -  Immunosuppressive corticosteroid doses (&gt; 10 mg prednisone daily or equivalent) within&#xD;
             4 weeks prior to the first dose of trial medication except for control of cerebral&#xD;
             edema in case of recurrent glioblastoma (cohort D).&#xD;
&#xD;
          -  Current or prior treatment with any systemic anti-cancer therapy (including&#xD;
             radiotherapy) either within 28 days or a minimum of 5 half-lives, whichever is shorter&#xD;
             before start of treatment&#xD;
&#xD;
          -  Serious concomitant disease, especially those affecting compliance with trial&#xD;
             requirements or which are considered relevant for the evaluation of the endpoints of&#xD;
             the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers&#xD;
             (gastrointestinal tract, skin) or laboratory abnormality that may increase the risk&#xD;
             associated with trial participation or trial drug administration, and in the judgment&#xD;
             of the investigator would make the patient inappropriate for entry into the trial.&#xD;
&#xD;
          -  Major injuries and/or surgery or bone fracture within 4 weeks of start of treatment,&#xD;
             or planned surgical procedures during the trial period.&#xD;
&#xD;
          -  Patients with personal or family history of QT prolongation and/or long QT syndrome,&#xD;
             or prolonged QTcF at baseline (&gt; 480 ms).&#xD;
&#xD;
          -  Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension,&#xD;
             unstable angina, history of infarction within past 6 months, congestive heart failure&#xD;
             &gt; NYHA II).&#xD;
&#xD;
        Uncontrolled hypertension defined as: Blood pressure in rested and relaxed condition &gt;= 140&#xD;
        mmHg, systolic or &gt;= 90 mmHg diastolic (with or without medication), measured according to&#xD;
        Appendix 10.2.&#xD;
&#xD;
          -  LVEF &lt; 50%&#xD;
&#xD;
          -  History of severe hemorrhagic or thromboembolic event in the past 12 months (excluding&#xD;
             central venous catheter thrombosis and peripheral deep vein thrombosis).&#xD;
&#xD;
          -  Known inherited predisposition to bleeding or to thrombosis in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Patient with brain metastases that are symptomatic and/or require therapy.&#xD;
&#xD;
          -  Patients who require full-dose anticoagulation (according to local guidelines).&#xD;
&#xD;
          -  No Vitamin K antagonist and other anticoagulation allowed; LMWH allowed only for&#xD;
             prevention not for curative treatment.&#xD;
&#xD;
          -  History of pneumonitis (non-infectious) within the last 5 years&#xD;
&#xD;
          -  Patients who are under judicial protection and patients who are legally&#xD;
             institutionalized.&#xD;
&#xD;
          -  Patients unable or unwilling to comply with protocol&#xD;
&#xD;
          -  Previous enrolment in this trial.&#xD;
&#xD;
          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,&#xD;
             makes them an unreliable trial patient or unlikely to complete the trial.&#xD;
&#xD;
          -  Women who are pregnant, nursing, or who plan to become pregnant in the trial&#xD;
&#xD;
          -  UncontrolledSymptomatic pleural effusion, pericardial effusion, or ascites&#xD;
&#xD;
          -  Prior treatment with any antiangiogenic treatment (e.g. bevacizumab, cediranib,&#xD;
             aflibercept, vandetanib, XL-184, sunitinib, etc) except for sorafenib and lenvatinib&#xD;
             in 2nd line HCC cohort (Cohort F)&#xD;
&#xD;
          -  Has received a live vaccine within 30 days prior to the first dose of study drug&#xD;
&#xD;
          -  Patients with known active second malignancy other than non-melanoma skin cancers,&#xD;
             non-metastatic prostate cancer, in situ cervical cancer, and ductal or lobular&#xD;
             carcinoma in situ of the breast. Patients are not considered to have a currently&#xD;
             active malignancy if they have completed anticancer therapy and have been disease free&#xD;
             for greater than 2 years prior to screening&#xD;
&#xD;
          -  Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Robert-Vizcarrondo</last_name>
      <phone>+001(205)975-4077</phone>
      <email>frobert@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Berz</last_name>
      <phone>+001(310)432-8952</phone>
      <email>dberz@BHCancerCenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Harvey</last_name>
      <phone>+001(404)778-4381</phone>
      <email>rdharve@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Hodi</last_name>
      <phone>+001(617)632-4715</phone>
      <email>stephen_hodi@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Otterson</last_name>
      <phone>+001(614)293-9424</phone>
      <email>greg.otterson@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prisma Health</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Edenfield</last_name>
      <phone>+001(864)679-3900</phone>
      <email>Jeffery.Edenfield@prismahealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siwen Hu-Lieskovan</last_name>
      <phone>+001(801)595-0255</phone>
      <email>Siwen.Hu-Lieskovan@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Spira</last_name>
      <phone>+001(703)280-5390</phone>
      <email>Alexander.Spira@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris Obrien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haowen Sim</last_name>
      <phone>61285140922</phone>
      <email>haowen.sim@lh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Pavlakis</last_name>
      <phone>61294631172</phone>
      <email>nick.pavlakis@sydney.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adnan Nagrial</last_name>
      <phone>61288905200</phone>
      <email>adnan.nagrial@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peninsula and South Eastern Oncology Group</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinod Ganju</last_name>
      <phone>61397815244</phone>
      <email>vg@paso.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cabrini Malvern Hospital</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Richardson</last_name>
      <phone>1300301977</phone>
      <email>gary.richardson@ocv.net.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Voskoboynik</last_name>
      <phone>61390762000</phone>
      <email>M.Voskoboynik@alfred.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Kim</last_name>
      <phone>+33(0)381479999</phone>
      <email>stefanokim@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTR Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Ghiringhelli</last_name>
      <phone>+33(0)380737528</phone>
      <email>FGhiringhelli@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Jeanson</last_name>
      <phone>+33(0)491384643</phone>
      <email>arnaud.jeanson@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>INS Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Girard</last_name>
      <phone>+33(0)144324606</phone>
      <email>nicolas.girard2@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTR Eugène Marquis</name>
      <address>
        <city>Rennes Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lesimple</last_name>
      <phone>+33(0)299253195</phone>
      <email>t.lesimple@rennes.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Nord Laennec</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Bordenave</last_name>
      <phone>+33(0)240165930</phone>
      <email>stephanie.bordenave@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline Mascaux</last_name>
      <phone>+33(0)369550378</phone>
      <email>celine.mascaux@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Hackanson</last_name>
      <phone>+49(821)4002729</phone>
      <email>bjoern.hackanson@uk-augsburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Wermke</last_name>
      <phone>+49(351)45815624</phone>
      <email>martin.wermke@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Burger</last_name>
      <phone>+49(69)6301-87711</phone>
      <email>michael.burger@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helge Bischoff</last_name>
      <phone>+49(6221)3961304</phone>
      <email>helge.bischoff@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Alt</last_name>
      <phone>496131176924</phone>
      <email>juergen.alt@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Schulz</last_name>
      <phone>+49(941)9447281</phone>
      <email>christian.schulz@ukr.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Lauer</last_name>
      <phone>+49(7071)2982722</phone>
      <email>ulrich.lauer@uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung Cheung Thomas Yau</last_name>
      <phone>+85222553111</phone>
      <email>the@netvigator.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noboru Yamamoto</last_name>
      <phone>+81335422511</phone>
      <email>nbryamam@ncc.go.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Seok Lee</last_name>
      <phone>82317877003</phone>
      <email>jslee0918@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-We Kim</last_name>
      <phone>82230103215</phone>
      <email>swkim@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Wan Kim</last_name>
      <phone>82220722995</phone>
      <email>kimdw@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinical Center, Gdansk</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafal Dziadziuszko</last_name>
      <phone>+48585844571</phone>
      <email>rafald@gumed.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mandziuk Slawomir Specialist Medical Practice</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Slawomir Mandziuk</last_name>
      <phone>+48817244851</phone>
      <email>slawman7@wp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>European Health Center Otwock</name>
      <address>
        <city>Otwock</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cezary Szczylik</last_name>
      <phone>+48227103035</phone>
      <email>cezary.szczylik@ecz-otwock.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MED POLONIA SP Z O O, Clinical Trials Department,Poznan</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodryg Ramlau</last_name>
      <phone>+48616561700</phone>
      <email>rramlau@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dom Lekarski S.A.</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Serwatowski</last_name>
      <phone>+48914427420</phone>
      <email>piotr.serwatowski@wp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onco.Cent. - Instit. of Maria Sklodowskiej-Curie</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iwona Lugowska</last_name>
      <phone>+48225463380</phone>
      <email>iwona.lugowska@coi.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSC &quot;Group of Companies &quot;Medsi&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeniy Ledin</last_name>
      <phone>+7(495)0237294</phone>
      <email>ledin@inbox.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budget Healthcare Institution &quot;Saint-Petersburg clinical research center of specialized types of medical care (oncological)&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fedor Moiseenko</last_name>
      <phone>+7(812)573-91-31</phone>
      <email>moiseenkofv@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budget Healthcare Institution &quot;Volgograd Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadezhda Kovalenko</last_name>
      <phone>+8(8442)584869</phone>
      <email>kovalenkost@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier García Corbacho</last_name>
      <phone>+34932275400ext.380748</phone>
      <email>garcia33@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enriqueta Felip</last_name>
      <phone>+34932746077</phone>
      <email>efelip@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Gambardella</last_name>
      <phone>+34961973531</phone>
      <email>valen.gambardella@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NCKUH</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu Chou Su</last_name>
      <phone>886-6-2353535ext.3120</phone>
      <email>sunnysu@mail.ncku.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia Chi Lin</last_name>
      <phone>886223123456#67460</phone>
      <email>cclin1@ntu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Municipal Non-profit Enterprise &quot;City Clinical Hospital #4&quot; of Dnipro City Council, Chemotherapeutic Department with day pat</name>
      <address>
        <city>Dnipropetrovks</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Bondarenko</last_name>
      <phone>+380675625054</phone>
      <email>oncology@dsma.dp.ua</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncological Center</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Ponomarova</last_name>
      <phone>+380444240114</phone>
      <email>pola.pola59@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical and Preventive Treatment Inst. Volyn Regional, Lutsk</name>
      <address>
        <city>Lutsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Sinielnikov</last_name>
      <phone>+380503782998</phone>
      <email>ivan.sinielnikov@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vinnytsia Regional Clinical Oncological Dispensary</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volodymyr Shamrai</last_name>
      <phone>+380432435588</phone>
      <email>shamrai.onco@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Meyer</last_name>
      <phone>08451555000</phone>
      <email>t.meyer@ucl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

